

**SSIEM 2007**

Annual Symposium of the European Society on Inborn Errors of Metabolism

Hamburg, 4.9.2007 - 7.9.2007

# **ERNDIM Meeting on Diagnosis of Peroxisomal Disorders - Clinical Pointers**



**Jutta Gärtner**

Georg August University Göttingen

Dept. of Pediatrics and Pediatric  
Neurology



# Genetic Disorders of Peroxisomes

- **Multiple deficiencies - peroxisome biogenesis disorders (PBD)**
  - Zellweger syndrome spectrum (ZSS)
  - Rhizomelic chondrodysplasia punctata (RCDP)
- **Single function deficiencies**
  - peroxisomal  $\beta$ -oxidation (D-bifunctional protein deficiency, ...)
  - X-linked adrenoleukodystrophy (X-ALD)
  - others

# PBD - Zellweger Syndrome Spectrum

Mutated Gene	Patient #	Phenotype	%
<i>PEX1</i>	124	ZSS	54
<i>PEX5</i>	3	ZSS	1
<i>PEX12</i>	9	ZSS	4
<i>PEX6</i>	27	ZSS	12
<i>PEX10</i>	5	ZSS	2
<i>PEX26</i>	11	ZSS	5
<i>PEX16</i>	1	ZSS	<1
<i>PEX2</i>	3	ZSS	1
<i>PEX7</i>	44	RCDP	19
<i>PEX3</i>	2	ZSS	<1
<i>PEX13</i>	1	ZSS	<1
<i>PEX19</i>	1	ZSS	<1
<i>PEX14*</i>	1	ZSS	<1

ZSS: *PEX1* mutations most common

*PEX7* mutations only → RCDP  
all other *PEX* mutations → ZSS

modified from Gould and Valle, 2000  
\*Shimozawa N et al, 2004

# PBD - Zellweger Syndrome Spectrum

Mutated Gene	Patient #	Phenotype	%
<i>PEX1</i>	124	ZSS	54
<i>PEX5</i>	3	ZSS	1
<i>PEX12</i>	9	ZSS	4
<i>PEX6</i>	27	ZSS	12
<i>PEX10</i>	5	ZSS	2
<i>PEX26</i>	11	ZSS	5
<i>PEX16</i>	1	ZSS	<1
<i>PEX2</i>	3	ZSS	1
<i>PEX7</i>	44	RCDP	19
<i>PEX3</i>	2	ZSS	<1
<i>PEX13</i>	1	ZSS	<1
<i>PEX19</i>	1	ZSS	<1
<i>PEX14*</i>	1	ZSS	<1

Genotype-phenotype correlation:  
type of mutation and not the mutated *PEX* gene determines disease severity

modified from Gould and Valle, 2000  
\*Shimozawa N et al, 2004

# PBD - Zellweger Syndrome Spectrum



Besides classical forms also late clinical onset forms with secondary deterioration




PBD is a differential diagnosis of late-infantile onset leukencephalopathy

# Genetic Disorders of Peroxisomes - cMRI Findings

## Neuroradiological features in PBD and $\beta$ -oxidation defects - Summary

- Polymicrogyria
- Pachygyria
- Leukencephalopathy
- Germinoytic cysts
- Brain atrophy



# Impact of cMRI for PBD and $\beta$ -Oxidation Defects



cMRI findings can be highly suggestive for PBD or  $\beta$ -oxidation defects



further diagnostic work-up even in the absence of characteristic biochemical and/or clinical findings

# X-linked Adrenoleukodystrophy - General

## Incidence

1:20.000 males (1:16.000 males and females)

## Clinical phenotypes

- cerebral demyelinating forms
  - childhood and adolescent cerebral ALD
  - adult cerebral form
  - 35 % of males with AMN
- adrenomyeloneuropathy (AMN)
  - adult males (20-40y)
  - heterozygous women > 35 years
- Addison's disease only




# X-linked Adrenoleukodystrophy - *ALD* Gene

- Localization  
chromosome Xq28
- Gene Product - ALDP, ABCD1  
75 kDa peroxisomal membrane protein  
ABC (ATP-Binding Cassette) transporter protein family
- Gene Defect  
primary cause for all clinical phenotypes of X-ALD

***But***

Malfunction of ALDP alone does not explain the various clinical phenotypes

# X-linked Adrenoleukodystrophy - Pathophysiology




Monozygotic Twins with X-ALD and two distinct clinical phenotypes.

# X-linked Adrenoleukodystrophy - Pathophysiology

## Current strategies to find modifiers

- candidate gene approaches
  - immune systeme
  - protein-protein-interaction partners
  - others
- global gene and protein expression profiles
  - transcriptomics
  - proteomics
- genome wide scans
  - susceptibility loci and genes

# X-linked Adrenoleukodystrophy - Therapy



before

after

Bone marrow transplantation  
(HSCT) can reverse or stabilize  
CNS demyelination in cALD

*N Engl J Med, 1993*

*Lancet, 2000*

*Blood, 2004*

